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A 35-year-old man presented with a one month history of gingival bleeding. He was diagnosed with
Acute Myeloid Leukemia (AML-M3). During treatment he developed alveolar hemorrhage for which he
was treated with a steroid. After the steroid treatment he developed a nodule, a cavitary lesion and
atelectasia in the left lung. He was treated with voriconazole. After therapy with voriconazole his lesion
signiﬁcantly decreased. This case illustrates the efﬁcacy and safety of antifungal therapy with vor-
iconazole for aspergillosis complicated by AML.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute myeloid leukemia (AML) is a hematopoietic neoplasm of
themyeloid line of blood cells. Acute Promyelocytic Leukemia (APL)
is a biologically and clinically distinct form of AML. APL is rarely
seen in the ﬁrst decade but increases with the second decade and
into early adulthood [1]. APL patients present with symptoms such
as pancytopenia, fatigue, infection, bleeding gums, bleeding,
nosebleeds and disseminated intravascular coagulation [2].
Hematological malignancies are associated with many oppor-
tunistic infections including invasive aspergillosis (IA), an important
destructive fungal infection [3]. IA complicates 5e29% of the cases of
Acute Myeloid Leukemia (AML), and the risk is correlated with the
degree of immuno-suppression following chemotherapy [3e5].
Voriconazole is a triazole derivative which is frequently used
due to its potency, broad spectrum activity, clinical efﬁcacy, safety
and tolerance [6,7]. Numerous case studies and randomized control
trials have shown that voriconazole is superior to amphotericin B in
the treatment of IA and it is now considered the ﬁrst-line therapy inzi Kampüs, Van, Turkey. Tel.:
unbatar).
Ltd. This is an open access article umany treatment centers [8]. I.
Below we present a case of AML-ML complicated by invasive
aspergillosis treated with voriconazole.2. Case report
A 35-year-old man presented with a one-month history of fa-
tigue and gingival bleeding. Physical examination of the patient
revealed hepatomegaly. Complete blood count (CBC) showed low
counts with peripheral blasts. Subsequent bone marrow examina-
tion and immunophenotyping conﬁrmed the diagnosis of Acute
Myeloid Leukemia (AML-M3), but the patient refused treatment.
Fifteen days later, the patient was admitted to hospital with dete-
rioration of his overall condition. He received induction chemo-
therapy with All Trans Retinoic Acid (ATRA), cytarabine and
idarubicin. On the thirtieth day of chemotherapy, chest pain, dys-
pnea and hemoptysis occurred. Results of laboratory examination
were as follows: Hemoglobin: 8.5 g/dL, WBC: 1.4  109/L, Platelets:
60  109/L, PT 16 s, APTT: 26 s, INR of 1.3. On chest X-rays, ground
glass opasities were seen in both lungs. In the parenchymal win-
dow on the thorax CT, diffuse bilateral pulmonary alveolar hem-
orrhaging combined with patchy opacities were observed (Fig. 1).
The patient's condition was diagnosed as ATRA-dependent alveolar
hemorrhage and steroid treatment was begun (Dexametazon
2  10 mg/day). About 15 days after initiation of steroid treatment,
coughing and release of sputum started. On chest CT scans, in thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Alveolar hemorrhage after treatment of ATRA.
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cavitary lesion approximately 27  18 mm in size was observed
in the left upper lobe. In the left lower lobe mediobazal segment, an
atelactasis 7.5  4.5 cm in size was found, and in the right lower
lobe irregular nodules from 10 mm to 16 mm in size of the area
were observed (Fig. 2). Bronchoscopy was performed and bronchial
lavage taken. Tuberculosis culture and galactomannan were nega-
tive. Serial galactomannan antigen tests on the patient's bloodwere
performed. After 20 days galactomannan was positive and treat-
ment with voriconazole was started (Table 1). One mounth later
under voriconazole treatment, the left upper lobe cavitary lesion
and lower lobe atelectasis were found to have signiﬁcantly
decreased (Fig. 3). The patient is still being monitored in our clinic.
3. Discussion
Differentiation syndrome (DS), previously known as retinoicFig. 2. Before tacid syndrome, is themain life-threatening complication of therapy
with differentiating agents [either trans retinoic acid (ATRA) or
arsenic trioxide (ATO)]in patients with acute promyelocytic leu-
kemia (APL) [9]. Abnormal ﬁndings in chest radiography or
computerized tomography are very common during the course of
DS [10]. The typical ﬁndings on a chest radiograph are interstitial
inﬁltrates (i.e., septal lines and peribronchial cufﬁng, ground glass
opacity) and pleural effusion. An increased cardiothoracic ratio (up
to 87%) and parenchymal consolidation are also frequently
encountered (47%), with or without air bronchogram [11]. Also,
congestive heart failure and pneumonia in a febrile neutropenic
patient should be excluded from this pattern. In such cases eco-
cardiography, microbiologic isolates, patterns of fever, further
response to intravenous dexamethasone or antibiotics, and the
clinical and radiological course will aid in diagnosis. Notably, an
association between the occurrence of DS and disseminated
intravascular coagulopathy and haemorragic syndrome, includingreatment.
Table 1
Prognosis scheme during treatment.
Fig. 3. After treatment.
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suggest that, at least in some cases, DS and pulmonary hemorrhage
may occur concomitantly as part of the same pathogenic process.
It was thought that pulmonary hemorrhage was rarely a
complication of ATRA; when our patient presented accordingly,
ATRA treatment was stopped and steroid treatment was started.
After two weeks of symptoms the patient partially regressed but
new radiological abnormalities occurred.
Invasive aspergillosis (IA) is an infection frequently found in
AML patients undergoing induction chemotherapy. Both acute
infection and relapse are particularly associated with severe neu-
tropenia, the use of broad-spectrum antibiotics or high-dose cor-
ticosteroids. IA patients have a higher risk of reactivation of the
infection with further chemotherapy, probably due to the fact that
fungal organisms remain viable in the initial lesions [13]. Patientswith acute leukemia and a history of previously treated IA on
additional chemotherapy are at an approximately 50% risk for
recurrent invasive aspergillosis. Due to the higher beneﬁt-risk ratio
it is universally accepted that IA is not an absolute contraindication
for further chemotherapy [14e16]. The diagnosis of invasive
aspergillosis may be difﬁcult to conﬁrm. One of the problems in
diagnosing invasive pulmonary aspergillosis is that the isolation of
Aspergillus from respiratory secretions or its presence on a Gram
stain preparation may be misleading, because the fungus can be a
colonizing organism or the result of laboratory contamination as
well. The diagnosis of invasive aspergillosis requires presence of the
fungus in tissue specimens. Also, Aspergillus infection should be
conﬁrmed by culture, since it cannot be diagnosed with certainty
by microscopy. Many patients with documented invasive asper-
gillosis have negative cultures. This has been observed in
H. Gunbatar et al. / Respiratory Medicine Case Reports 16 (2015) 65e6868surveillance studies, and the prevalence of negative cultures varies
depending on the population being evaluated. As an example, in
multicenter surveillance studies, only 25 to 50% of hematopoietic
cell transplant recipients who met criteria for invasive aspergillosis
based upon galactomannan antigen results had positive cultures
[17,18].
Radiological imaging remains the cornerstone with the “halo”
sign and “crescent” sign on CT scans being regarded as diagnostic
for invasive pulmonary aspergillosis. Pulmonary aspergillosis
typically manifests itself as single or multiple nodules with or
without cavitation, patchy or segmental consolidation, or peri-
bronchial inﬁltrates with or without tree-in-bud patterns. One
relatively large review noted that small nodules (<1 cm) were most
common (20 of 46; 43%), followed by consolidation (12 of 46; 26%),
large nodules (masses, 10 of 46; 21%), and peribronchial inﬁltrates
(4 of 46; 9%) [19]. Another large study that included neutropenic
and nonneutropenic patients showed that the more speciﬁc signs
(nodules and cavitation) were infrequent, with principal radio-
graphic ﬁndings including consolidation, ground-glass inﬁltrates,
and pleural effusions [20]. In febrile neutropenic patients, sys-
tematic CT scans allow earlier diagnosis of IPA [21]. Deﬁnitive
diagnosis depends on tissue biopsy, which may not be feasible,
depending on the degree of cytopenia and coagulation abnormal-
ities in such patients.
Antifungal therapy remains the mainstay of treatment for
invasive aspergillosis [22]. However, the combination of antifungal
treatment and surgical resection has been shown to dramatically
improve the prognosis of IA. Aggressive surgical resection has been
associated with improved outcome by eliminatingmacroscopic foci
of IA that could complicate subsequent immunosuppressive
chemotherapy; although due to the fact that IA is a multifocal
disease at least at microscopic level, even surgical excision does not
guarantee a complete cure [23]. The risk of leukemia relapse or the
presence of multiple and bilateral lesions does not allow for the
surgery. Thus secondary antifungal prophylaxis is the main option
for such patients [10]. Voriconazole is a new broad spectrum tri-
azole that is active in vitro against various yeasts and molds,
including aspergillus species. Recent data [24] show better re-
sponses (52.8 vs. 31.6% at 12 weeks), improved survival (70.8 vs.
57.9%) and fewer side effects with voriconazole compared to the
standard approach of initial therapy with amphotericin B. Treat-
ment failures after use of liposomal amphotericin B have been
successfully treated with voriconazole [25,26].
In this case report, a high-risk acute myeloid leukemia patient
underwent chemotherapy and steroid treatment after alveolar
hemorrhage aggravated by a fungal infection. A well-tolerated and
successful treatment with voriconazole decreased the pulmonary
cavity and inﬁltration. Nevertheless, it should be noted that the
observation periods for our case and also for those reported in the
literature are relatively short.
In conclusion, ATRA-induced pulmonary hemorrhage is a rare
complication. This needs to be kept in mind as a potential
complication. If it does not respond to ﬁrst-line treatment, infec-
tious causes such as invasive aspergillosis should be considered,
and treatment should be started early.
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